# Product Pipeline

***Neratinib*: *Tyrosine kinase inhibitor***

**HER2+ Breast Cancer**

- **Extended adjuvant**
  *Neratinib monotherapy*
- **Metastatic**
  *Monotherapy or combo therapy*
- **Metastatic w/ brain mets**
  *Monotherapy or combo therapy*

***Alisertib*: *Aurora kinase A inhibitor***

**HRc+*** HER2-negative MBC**

**Metastatic EGFR-mutant NSCLC****

**Small cell lung cancer**

- ExteNET (Phase III HER2+ EBC*)
- CONTROL
- NALA (Phase III 3rd Line HER2+ MBC**)
- TBCRC-022 (T-DM1 + neratinib)
- TBCRC-041 (fulvestrant + alisertib)
- ALISCA™-Breast1 (alisertib+endocrine) — *Initiation in Q4 '24*
- NCT04085315 (alisertib+osimertinib)
- NCT02038647 (paclitaxel + alisertib)
- ALISCA™-Lung1 (PUMA-ALI-4201) — *Initiated in Q1'24*

Copyright 2024 Puma Biotechnology

* ECB: Early breast cancer ** MBC: Metastatic breast cancer *** HRc+: Hormone receptor positive **** NSCLC: Non small cell lung cancer